ADME-Enabling Technologies in Drug Design and Development

Front Cover
Donglu Zhang, Sekhar Surapaneni
Wiley, Apr 13, 2012 - Science - 800 pages
0 Reviews

A comprehensive guide to cutting-edge tools in ADME research

The last decade has seen tremendous progress in the development of analytical techniques such as mass spectrometry and molecular biology tools, resulting in important advances in drug discovery, particularly in the area of absorption, distribution, metabolism, and excretion (ADME).

ADME-Enabling Technologies in Drug Design and Development focuses on the current state of the art in the field, presenting a comprehensive review of the latest tools for generating ADME data in drug discovery. It examines the broadest possible range of available technologies, giving readers the information they need to choose the right tool for a given application, a key requisite for obtaining favorable results in a timely fashion for regulatory filings. With over thirty contributed chapters by an international team of experts, the book provides:

  • A thorough examination of current tools, covering both electronic/mechanical technologies and biologically based ones

  • Coverage of applications for each technology, including key parameters, optimal conditions for intended results, protocols, and case studies

  • Detailed discussion of emerging tools and techniques, from stem cells and genetically modified animal models to imaging technologies

  • Numerous figures and diagrams throughout the text

Scientists and researchers in drug metabolism, pharmacology, medicinal chemistry, pharmaceutics, toxicology, and bioanalytical science will find ADME-Enabling Technologies in Drug Design and Development an invaluable guide to the entire drug development process, from discovery to regulatory issues.

What people are saying - Write a review

We haven't found any reviews in the usual places.

Other editions - View all

About the author (2012)

Donglu Zhang, PhD, is a Principal Scientist in Pharmaceutical Candidate Optimization at Bristol-Myers Squibb in Princeton, New Jersey. He has published seventy peer-reviewed articles, codiscovered the Mass Defect Filtering technique, and coedited two books.

Sekhar Surapaneni, PhD, is Director, DMPK, at Celgene Corporation in New Jersey. He has published extensively in peer-reviewed journals and is a member of ISSX and ACS.

Bibliographic information